5-O-Acetylpinostrobin derivatives inhibit estrogen alpha and progesterone receptors through a molecular docking approach
DOI:
https://doi.org/10.46542/pe.2024.243.244250Keywords:
5-O-acetylpinostrobin, Breast cancer, Molecular dockingAbstract
Background: Among all cancers, breast cancer accounts for 11.7% of new cases and 6.9% of deaths worldwide. This is driven by increased estrogen receptor alpha (ERα) and progesterone receptor (PgR) expression. Many breast cancer drugs cause various side effects. Modifying the structure of pinostrobin by adding acyl groups to obtain 5-O-acetylpinostrobin derivatives can increase its activity and selectivity.
Objective: This study aimed to predict the interaction of 5-O-acetylpinostrobin derivatives with ERα and PgR.
Method: A molecular docking approach using AutodockTool. The Protein Data Bank (PDB) was used to obtain ID 3ERT (ERα) and 2W8Y (PgR).
Result: The analysis showed the value of free energy binding (ΔG) to ERα with a range of -8.58 to -5.76 kcal/mol and an inhibition concentration (Ki) of 0.51 to 59.91 μM. PgR had ΔG values of -12.37 to -8.30 kcal/mol and Ki of 0.86 to 830.64 nM.
Conclusion: The study showed that 5-O-4-(dimethylamino)benzoylpinostrobin, 5-O-cyclohexancarbonylpinostrobin, 5-O-2-phenylacetylpinostrobin, 5-O-3-phenylpropanoylpinostrobin, and 5-O-cyclobutanecarbonylpinostrobin have the potential to be synthesised and serve as the basis for the development of new anticancer compounds that inhibit ERα and PgR in breast cancer.
References
Acharya, R., Chacko, S., Bose, P., Lapenna, A., & Pattanayak, S. P. (2019). Structure based multitargeted molecular docking analysis of selected furanocoumarins against breast cancer. Scientific Reports, 9(1), 15743. https://doi.org/10.1038/s41598-019-52162-0
Feng, Y., Spezia, M., Huang, S., Yuan, C., Zeng, Z., Zhang, L., Ji, X., Liu, W., Huang, B., Luo, W., Liu, B., Lei, Y., Du, S., Vuppalapati, A., Luu, H. H., Haydon, R. C., He, T. C., & Ren, G. (2018). Breast cancer development and progression: Risk factors, cancer stem cells, signaling pathways, genomics, and molecular pathogenesis. Genes and Diseases, 5(2), 77–106. https://doi.org/10.1016/j.gendis.2018.05.001
Hilton, H. N., Clarke, C. L., & Graham, J. D. (2018). Estrogen and progesterone signalling in the normal breast and its implications for cancer development. Molecular and Cellular Endocrinology, 466, 2–14. https://doi.org/10.1016/j.mce.2017.08.011
International Agency for Research on Cancer. (2020). Cancer today. https://gco.iarc.fr/today/online
Jones, A. A., & Gehler, S. (2020). Acacetin and pinostrobin inhibit malignant breast epithelial cell adhesion and focal adhesion formation to attenuate cell migration. Integrative Cancer Therapies, 19. https://doi.org/10.1177/1534735420918945
Lashen, A. G., Toss, M. S., Mongan, N. P., Green, A. R., & Rakha, E. A. (2023). The clinical value of progesterone receptor expression in luminal breast cancer: A study of a large cohort with long-term follow-up. Cancer, 129(8), 1183–1194. https://doi.org/10.1002/cncr.34655
Mani, S., Swargiary, G., Gulati, S., Gupta, S., & Jindal, D. (2023). Molecular docking and ADMET studies to predict the anti-breast cancer effect of aloin by targeting estrogen and progesterone receptors. Materials Today: Proceedings, 80, 2378–2384. https://doi.org/10.1016/j.matpr.2021.06.362
Mehmood, Y., Anwar, F., Saleem, U., Hira, S., Ahmad, B., Bashir, M., Imtiaz, M. T., Najm, S., & Ismail, T. (2021). The anti-cancer potential of 2,4,6 tris-methyphenylamino1,3,5-triazine compound against mammary glands cancer: Via down-regulating the hormonal, inflammatory mediators, and oxidative stress. Life Sciences, 285, 119994. https://doi.org/10.1016/j.lfs.2021.119994
Norhayati, Ekowati, J., Diyah, N. W., Tejo, B. A., & Ahmed, S. (2023). Chemoinformatics approach to design and develop vanillin analogs as COX-1 inhibitor. Journal of Public Health in Africa, 14(S1), 2517. https://doi.org/10.4081/jphia.2023.2517
Ongwisespaiboon, O., & Jiraungkoorskul, W. (2017). Fingerroot, Boesenbergia rotunda and its aphrodisiac activity. Pharmacognosy Reviews, 11(21), 27–30. https://doi.org/10.4103/phrev.phrev_50_16
Patel, N. K., Jaiswal, G., & Bhutani, K. K. (2016). A review on biological sources, chemistry and pharmacological activities of pinostrobin. Natural Product Research, 30(18), 2017–2027. https://doi.org/10.1080/14786419.2015.1107556
Poerwono, H., Sasaki, S., Hattori, Y., & Higashiyama, K. (2010). Bioorganic & medicinal chemistry letters efficient microwave-assisted prenylation of pinostrobin and biological evaluation of its derivatives as antitumor agents. Bioorganic & Medicinal Chemistry Letters, 20(7), 2086–2089. https://doi.org/10.1016/j.bmcl.2010.02.068
Praditapuspa, E. N., Siswandono, & Widiandani, T. (2021). In silico analysis of pinostrobin derivatives from boesenbergia pandurata on ErbB4 kinase target and QSPR linear models to predict drug clearance for searching anti-breast cancer drug candidates. Pharmacognosy Journal, 13(5), 1143–1149. https://doi.org/10.5530/pj.2021.13.147
Siswandono, Widyowati, R., Suryadi, A., Widiandani, T., & Prismawan, D. (2020). Molecular modeling, synthesis, and qsar of 5-o-acylpinostrobin derivatives as promising analgesic agent. Rasayan Journal of Chemistry, 13(4), 2559–2568. https://doi.org/10.31788/RJC.2020.1345749
Sukardiman, Widyawaruyanti, A., Widyowati, R., Sismindari, & Zaini, N. C. (2014). Pinostrobin isolated from Kaempferia pandurata Roxb induced apoptosis in T47D human breast cancer cell line. E-Journal Planta Husada, 2(1), 20–26.
TilakVijay, J., Vivek Babu, K., & Uma, A. (2019). Virtual screening of novel compounds as potential erα inhibitors. Bioinformation, 15(5), 321–332. https://doi.org/10.6026/97320630015321
